Connecticut Oncology Association


The Connecticut Oncology Association represents more than 100 physicians and other health care professionals who care for cancer patients. The Society is a non-profit corporation devoted to the improvement of hematologic and oncologic care of patients.

Membership in the Society is open to physicians, allied health professionals, and institutions with a demonstrated interest and involvement in the care of patients with hematologic and oncologic disorders. It is also open to residents and fellows who are actively enrolled in a full-time residency program in hematology or oncology in Connecticut or who are in an appropriate fellowship program. Corporate entities involved in the care and treatment of cancer patients may also become members.

The Connecticut Oncology Association is grateful to our Corporate Sponsors, whose donations help us fulfill our mission.

Stay up to date on the latest cancer related bills in the Connecticut Legislature (Login required)


Upcoming Meetings & Events

Go to Events page for more information

News From Charter Oak Corporate Sponsors:

09/30/2019 Genentech Presents Positive Phase III Results  Press Release

09/30/2019 AstraZeneca - Tagrisso is the only 1st-line treatment for EGFR-mutated non-small cell lung cancer to deliver a median overall survival of more than three years Press Release

08/16/2-19 Celgene -

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis  Press Release

09/29/2019 Merck - Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)  Press Release

10/01/2018 Takeda - Positive Results Press Release 

09/25/2018 AstraZeneca - Overall Survival Press Release 

09/24/2018 Astellas - Postive CHMP Opinion Press Release

08/06/2018 Teva - Updated Indication Press Release

06/28/2018 Array BioPharma - New Indication - BRAFTOVI™ (encorafenib) Press Release 

03/26/2018 Seattle Genetics - FDA Breakthrough Therapy Designation Press Release

N02-11-2016  Merck - New Indication  PressRelease.pdf

12-15-2015 - Genentech - ALECENSA® (alectinib)  ALECENSAPracticeManagerDay1Letters_ATP.pdf

Cancer News

Payment for Event - $50 for non-member or additional Corporate Partner (Must Register separately)

Connecticut Oncology Association (CtOA)

c/o Dawn Holcombe

33 Woodmar Circle
South Windsor, CT  06074
(860) 305-4510
(860) 644-9119 (FAX)

Website design by Sister Webs Design Studio, where 5% of profits are donated to women's cancer funds

Powered by Wild Apricot Membership Software